We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+30.53%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$706M
AUM Growth
+$74.9M
Cap. Flow
+$18.2M
Cap. Flow %
2.57%
Top 10 Hldgs %
71.67%
Holding
75
New
24
Increased
13
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$40.9M
2
LLY icon
Eli Lilly
LLY
+$20.8M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.3M
4
QURE icon
uniQure
QURE
+$14.1M
5
CDTX
Cidara Therapeutics
CDTX
+$11.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$40.4M
2
MRUS
Merus
MRUS
+$27.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.6M
4
BSX icon
Boston Scientific
BSX
+$17.9M
5
ARGX icon
argenx
ARGX
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.71%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
51
Praxis Precision Medicines
PRAX
$10.4B
$737K 0.1%
+2,500
New +$466K
ANRO icon
52
Alto Neuroscience
ANRO
$1.11B
$520K 0.07%
+29,192
New +$368K
TENX icon
53
Tenax Therapeutics
TENX
$499M
$513K 0.07%
+42,080
New +$366K
KOD icon
54
Kodiak Sciences
KOD
$2.82B
$476K 0.07%
+17,019
New +$349K
LYRA
55
DELISTED
LYRA THERAPEUTICS INC
LYRA
$27K ﹤0.01%
+8,756
New +$43.6K
ALEC icon
56
Alector
ALEC
$170M
– –
-71,029
Closed -$210K
BHVN icon
57
Biohaven
BHVN
$2.14B
– –
-80,000
Closed -$1.2M
BSX icon
58
Boston Scientific
BSX
$72.3B
– –
-183,200
Closed -$17.9M
CNTA
59
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-133,291
Closed -$3.23M
INSM icon
60
CALL
Insmed
INSM
$28.2B
– –
-400,000
Closed -$57.6M
IREN icon
61
Iris Energy
IREN
$14.1B
– –
-33,200
Closed -$1.56M
KALV
62
DELISTED
KalVista Pharmaceuticals
KALV
– –
-41,555
Closed -$506K
MREO
63
Mereo BioPharma
MREO
$47.7M
– –
-475,361
Closed -$979K
MRNA icon
64
Moderna
MRNA
$21.8B
– –
-23,800
Closed -$615K
MRUS
65
DELISTED
Merus
MRUS
– –
-296,750
Closed -$27.9M
NKTR icon
66
Nektar Therapeutics
NKTR
$2.48B
– –
-57,999
Closed -$3.3M
RARE icon
67
CALL
Ultragenyx Pharmaceutical
RARE
$2.48B
– –
-150,000
Closed -$4.51M
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.48B
– –
-64,502
Closed -$1.94M
REGN icon
69
Regeneron Pharmaceuticals
REGN
$78.8B
– –
-10,671
Closed -$6M
SRPT icon
70
Sarepta Therapeutics
SRPT
$1.81B
– –
-44,900
Closed -$865K
TGTX icon
71
TG Therapeutics
TGTX
$7.62B
– –
-54,515
Closed -$1.97M
VRNA
72
DELISTED
Verona Pharma
VRNA
– –
-379,004
Closed -$40.4M
VRTX icon
73
Vertex Pharmaceuticals
VRTX
$123B
– –
-55,100
Closed -$21.6M
ATYR
74
CALL
aTyr Pharma
ATYR
$48.1M
– –
-600,000
Closed -$433K
ATYR
75
aTyr Pharma
ATYR
$48.1M
– –
-372,276
Closed -$269K
1 2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 19.71% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
DAC
Dividend Assets Capital Ridgeland, South Carolina $501M AUM 13.71% 1-Year Est. Return
AA
Auxano Advisors Bellevue, Washington $501M AUM 24.15% 1-Year Est. Return

Artia Global Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Artia Global Partners held 75 positions worth $706M, up 12% from $631M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Artia Global Partners's Q4 2025 filing shows 24 new, 13 increased, 7 reduced and 20 closed positions. Its largest new stake was Cidara Therapeutics: 70,824 shares worth $15.6M. The largest sale was Verona Pharma, an estimated $40.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials.

  • Artia Global Partners's largest Q4 2025 buy was Cidara Therapeutics: 70,824 shares worth $15.6M.
  • Artia Global Partners added most to Abivax in Q4 2025, an estimated $40.9M increase.
  • Artia Global Partners's biggest Q4 2025 reduction was argenx, cutting an estimated $11.7M.
  • Artia Global Partners fully exited Verona Pharma in Q4 2025, selling an estimated $40.4M.
  • Artia Global Partners's ten largest holdings make up 72% of its $706M portfolio in Q4 2025.
  • Artia Global Partners opened 24 new positions and closed 20 in Q4 2025.
  • Artia Global Partners's portfolio value rose 12% quarter-over-quarter to $706M.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.